Literature DB >> 12021366

Envelope-dependent, cyclophilin-independent effects of glycosaminoglycans on human immunodeficiency virus type 1 attachment and infection.

Yi-Jun Zhang1, Theodora Hatziioannou, Trinity Zang, Douglas Braaten, Jeremy Luban, Stephen P Goff, Paul D Bieniasz.   

Abstract

Cell surface glycosaminoglycans (GAGs), in particular heparan sulfate (HS), have been proposed to mediate the attachment of human immunodeficiency virus type 1 (HIV-1) to target cells prior to virus entry, and both the viral gp120 envelope protein and virion-associated cyclophilin A (CypA) have been shown to directly interact with HS and its analogues. To determine the role of GAGs in HIV attachment and infection, we generated HIV-susceptible derivatives of CHO cell lines that either express high levels of GAGs (CHO-K1) or lack GAGs (pgsA745). Using a panel of HIV-1 envelopes, we found that cell surface GAG-mediated effects on virion attachment and infection vary in an envelope strain-dependent but coreceptor-independent manner. In fact, cell surface GAG-mediated enhancement of infection is confined to isolates that contain a highly positively charged V3-loop sequence, while infection by most strains is apparently inhibited by the presence of GAGs. Moreover, the enhancing and inhibitory effects of polycations and polyanions on HIV-1 infection are largely dependent on the presence of cell surface GAGs. These observations are consistent with a model in which GAGs influence in vitro HIV-1 infection primarily by modifying the charge characteristics of the target cell surface. Finally, the effects of GAGs on HIV-1 infection are observed to an equivalent extent whether CypA is present in or absent from virions. Overall, these data exclude a major role for GAGs in mediating the attachment of many HIV-1 strains to target cells via interactions with virion-associated gp120 or CypA.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12021366      PMCID: PMC136233          DOI: 10.1128/jvi.76.12.6332-6343.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  Molecular interaction between HIV-1 major envelope glycoprotein and dextran sulfate.

Authors:  E Mbemba; V Chams; J C Gluckman; D Klatzmann; L Gattegno
Journal:  Biochim Biophys Acta       Date:  1992-01-16

2.  Identification of envelope V3 loop as the major determinant of CD4 neutralization sensitivity of HIV-1.

Authors:  S S Hwang; T J Boyle; H K Lyerly; B R Cullen
Journal:  Science       Date:  1992-07-24       Impact factor: 47.728

3.  Dextran sulphate, a potent anti-HIV agent in vitro having synergism with zidovudine.

Authors:  R Ueno; S Kuno
Journal:  Lancet       Date:  1987-06-13       Impact factor: 79.321

4.  Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus, and human immunodeficiency virus.

Authors:  M Baba; R Snoeck; R Pauwels; E de Clercq
Journal:  Antimicrob Agents Chemother       Date:  1988-11       Impact factor: 5.191

5.  Cell-surface heparan sulfate proteoglycan mediates HIV-1 infection of T-cell lines.

Authors:  M Patel; M Yanagishita; G Roderiquez; D C Bou-Habib; T Oravecz; V C Hascall; M A Norcross
Journal:  AIDS Res Hum Retroviruses       Date:  1993-02       Impact factor: 2.205

6.  Tumor formation dependent on proteoglycan biosynthesis.

Authors:  J D Esko; K S Rostand; J L Weinke
Journal:  Science       Date:  1988-08-26       Impact factor: 47.728

7.  Animal cell mutants defective in glycosaminoglycan biosynthesis.

Authors:  J D Esko; T E Stewart; W H Taylor
Journal:  Proc Natl Acad Sci U S A       Date:  1985-05       Impact factor: 11.205

8.  Investigations into the mechanism by which sulfated polysaccharides inhibit HIV infection in vitro.

Authors:  M O McClure; J P Moore; D F Blanc; P Scotting; G M Cook; R J Keynes; J N Weber; D Davies; R A Weiss
Journal:  AIDS Res Hum Retroviruses       Date:  1992-01       Impact factor: 2.205

9.  Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B.

Authors:  J Luban; K L Bossolt; E K Franke; G V Kalpana; S P Goff
Journal:  Cell       Date:  1993-06-18       Impact factor: 41.582

10.  Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type 1 without interfering with gp120-CD4 interactions.

Authors:  L N Callahan; M Phelan; M Mallinson; M A Norcross
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

View more
  60 in total

Review 1.  Role of heparan sulfate in sexually transmitted infections.

Authors:  Vaibhav Tiwari; Erika Maus; Ira M Sigar; Kyle H Ramsey; Deepak Shukla
Journal:  Glycobiology       Date:  2012-07-06       Impact factor: 4.313

2.  Detection and Tracking of Dual-Labeled HIV Particles Using Wide-Field Live Cell Imaging to Follow Viral Core Integrity.

Authors:  João I Mamede; Thomas J Hope
Journal:  Methods Mol Biol       Date:  2016

3.  Restriction of human immunodeficiency virus type 1 by TRIM-CypA occurs with rapid kinetics and independently of cytoplasmic bodies, ubiquitin, and proteasome activity.

Authors:  David Perez-Caballero; Theodora Hatziioannou; Fengwen Zhang; Simone Cowan; Paul D Bieniasz
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

4.  Viral inhibition studies on sulfated lignin, a chemically modified biopolymer and a potential mimic of heparan sulfate.

Authors:  Arjun Raghuraman; Vaibhav Tiwari; Qian Zhao; Deepak Shukla; Asim K Debnath; Umesh R Desai
Journal:  Biomacromolecules       Date:  2007-04-17       Impact factor: 6.988

5.  Directional spread of surface-associated retroviruses regulated by differential virus-cell interactions.

Authors:  Nathan M Sherer; Jing Jin; Walther Mothes
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

6.  Cyclophilin interactions with incoming human immunodeficiency virus type 1 capsids with opposing effects on infectivity in human cells.

Authors:  Theodora Hatziioannou; David Perez-Caballero; Simone Cowan; Paul D Bieniasz
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

7.  Adaptation to the interferon-induced antiviral state by human and simian immunodeficiency viruses.

Authors:  Julia Bitzegeio; Marissa Sampias; Paul D Bieniasz; Theodora Hatziioannou
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

8.  Maturation of blood-derived dendritic cells enhances human immunodeficiency virus type 1 capture and transmission.

Authors:  Nuria Izquierdo-Useros; Julià Blanco; Itziar Erkizia; Maria Teresa Fernández-Figueras; Francesc E Borràs; Mar Naranjo-Gómez; Margarita Bofill; Lidia Ruiz; Bonaventura Clotet; Javier Martinez-Picado
Journal:  J Virol       Date:  2007-05-02       Impact factor: 5.103

9.  Polyclonal immunoglobulin G from patients neutralizes human immunodeficiency virus type 1 primary isolates by binding free virions, but without interfering with an initial CD4-independent attachment of the virus to primary blood mononuclear cells.

Authors:  Renaud Burrer; Sandrine Haessig-Einius; Anne-Marie Aubertin; Christiane Moog
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

10.  Structure activity relationship of dendrimer microbicides with dual action antiviral activity.

Authors:  David Tyssen; Scott A Henderson; Adam Johnson; Jasminka Sterjovski; Katie Moore; Jennifer La; Mark Zanin; Secondo Sonza; Peter Karellas; Michael P Giannis; Guy Krippner; Steve Wesselingh; Tom McCarthy; Paul R Gorry; Paul A Ramsland; Richard Cone; Jeremy R A Paull; Gareth R Lewis; Gilda Tachedjian
Journal:  PLoS One       Date:  2010-08-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.